A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma

Dalia Somjen, Sara Katzburg, Nava Nevo, Batya Gayer, Richard P. Hodge, Misty D. Renevey, Vyacheslav Kalchenko, Asher Meshorer, Naftali Stern, Fortune Kohen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The use of daunomycin against neoplasms is limited due to its severe cardiotoxicity. The cytotoxicity of daunomycin can be minimized by linking it to an affinity tag. Since ovarian cancer cells are sensitive to isoflavone action, we synthesized a daidzein daunomycin conjugate. In MLS human ovarian cancer cells, the conjugate was shown to have a larger cytotoxic effect than daunomycin per se at a low concentration. The conjugate was then tested in vivo in mice carrying MLS xenografts. Tumour growth in the groups of conjugate and daunomycin was inhibited by >50% as compared to vehicle treated mice. In contrast to daunomycin treated mice, no weight reduction or death was seen in mice treated with the conjugate. In vivo imaging of the fluorescence signal generated by daunomycin indicated uptake of both conjugate and daunomycin by the tumour. Tumour fluorescence was, however, higher in the conjugate treated mice than in the daunomycin treated mice, thus suggesting specific delivery of the drug to the tumour. Histological examination of myocardial tissue indicated that only the daunomycin, but not conjugate treated mice showed cardiac damage. These results indicate that targeting of daunomycin via carboxymethyldaidzein retains daunomycin's cytotoxic effects while averting its toxicity in an ovarian xenograft.

Original languageEnglish (US)
Pages (from-to)144-149
Number of pages6
JournalJournal of Steroid Biochemistry and Molecular Biology
Volume110
Issue number1-2
DOIs
StatePublished - May 2008

Fingerprint

Daunorubicin
Animals
Animal Models
Carcinoma
Tumors
Therapeutics
Neoplasms
Heterografts
Ovarian Neoplasms
daidzein
Fluorescence
Cells
Isoflavones
Optical Imaging
Cytotoxicity
Toxicity
Weight Loss

Keywords

  • Daidzein
  • Daunomycin
  • Isoflavone
  • Ovarian carcinoma
  • Site directed chemotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma. / Somjen, Dalia; Katzburg, Sara; Nevo, Nava; Gayer, Batya; Hodge, Richard P.; Renevey, Misty D.; Kalchenko, Vyacheslav; Meshorer, Asher; Stern, Naftali; Kohen, Fortune.

In: Journal of Steroid Biochemistry and Molecular Biology, Vol. 110, No. 1-2, 05.2008, p. 144-149.

Research output: Contribution to journalArticle

Somjen, D, Katzburg, S, Nevo, N, Gayer, B, Hodge, RP, Renevey, MD, Kalchenko, V, Meshorer, A, Stern, N & Kohen, F 2008, 'A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma', Journal of Steroid Biochemistry and Molecular Biology, vol. 110, no. 1-2, pp. 144-149. https://doi.org/10.1016/j.jsbmb.2008.03.033
Somjen, Dalia ; Katzburg, Sara ; Nevo, Nava ; Gayer, Batya ; Hodge, Richard P. ; Renevey, Misty D. ; Kalchenko, Vyacheslav ; Meshorer, Asher ; Stern, Naftali ; Kohen, Fortune. / A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma. In: Journal of Steroid Biochemistry and Molecular Biology. 2008 ; Vol. 110, No. 1-2. pp. 144-149.
@article{bf75288beb9f4eaf8fdb677cee6ed96a,
title = "A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma",
abstract = "The use of daunomycin against neoplasms is limited due to its severe cardiotoxicity. The cytotoxicity of daunomycin can be minimized by linking it to an affinity tag. Since ovarian cancer cells are sensitive to isoflavone action, we synthesized a daidzein daunomycin conjugate. In MLS human ovarian cancer cells, the conjugate was shown to have a larger cytotoxic effect than daunomycin per se at a low concentration. The conjugate was then tested in vivo in mice carrying MLS xenografts. Tumour growth in the groups of conjugate and daunomycin was inhibited by >50{\%} as compared to vehicle treated mice. In contrast to daunomycin treated mice, no weight reduction or death was seen in mice treated with the conjugate. In vivo imaging of the fluorescence signal generated by daunomycin indicated uptake of both conjugate and daunomycin by the tumour. Tumour fluorescence was, however, higher in the conjugate treated mice than in the daunomycin treated mice, thus suggesting specific delivery of the drug to the tumour. Histological examination of myocardial tissue indicated that only the daunomycin, but not conjugate treated mice showed cardiac damage. These results indicate that targeting of daunomycin via carboxymethyldaidzein retains daunomycin's cytotoxic effects while averting its toxicity in an ovarian xenograft.",
keywords = "Daidzein, Daunomycin, Isoflavone, Ovarian carcinoma, Site directed chemotherapy",
author = "Dalia Somjen and Sara Katzburg and Nava Nevo and Batya Gayer and Hodge, {Richard P.} and Renevey, {Misty D.} and Vyacheslav Kalchenko and Asher Meshorer and Naftali Stern and Fortune Kohen",
year = "2008",
month = "5",
doi = "10.1016/j.jsbmb.2008.03.033",
language = "English (US)",
volume = "110",
pages = "144--149",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1-2",

}

TY - JOUR

T1 - A daidzein-daunomycin conjugate improves the therapeutic response in an animal model of ovarian carcinoma

AU - Somjen, Dalia

AU - Katzburg, Sara

AU - Nevo, Nava

AU - Gayer, Batya

AU - Hodge, Richard P.

AU - Renevey, Misty D.

AU - Kalchenko, Vyacheslav

AU - Meshorer, Asher

AU - Stern, Naftali

AU - Kohen, Fortune

PY - 2008/5

Y1 - 2008/5

N2 - The use of daunomycin against neoplasms is limited due to its severe cardiotoxicity. The cytotoxicity of daunomycin can be minimized by linking it to an affinity tag. Since ovarian cancer cells are sensitive to isoflavone action, we synthesized a daidzein daunomycin conjugate. In MLS human ovarian cancer cells, the conjugate was shown to have a larger cytotoxic effect than daunomycin per se at a low concentration. The conjugate was then tested in vivo in mice carrying MLS xenografts. Tumour growth in the groups of conjugate and daunomycin was inhibited by >50% as compared to vehicle treated mice. In contrast to daunomycin treated mice, no weight reduction or death was seen in mice treated with the conjugate. In vivo imaging of the fluorescence signal generated by daunomycin indicated uptake of both conjugate and daunomycin by the tumour. Tumour fluorescence was, however, higher in the conjugate treated mice than in the daunomycin treated mice, thus suggesting specific delivery of the drug to the tumour. Histological examination of myocardial tissue indicated that only the daunomycin, but not conjugate treated mice showed cardiac damage. These results indicate that targeting of daunomycin via carboxymethyldaidzein retains daunomycin's cytotoxic effects while averting its toxicity in an ovarian xenograft.

AB - The use of daunomycin against neoplasms is limited due to its severe cardiotoxicity. The cytotoxicity of daunomycin can be minimized by linking it to an affinity tag. Since ovarian cancer cells are sensitive to isoflavone action, we synthesized a daidzein daunomycin conjugate. In MLS human ovarian cancer cells, the conjugate was shown to have a larger cytotoxic effect than daunomycin per se at a low concentration. The conjugate was then tested in vivo in mice carrying MLS xenografts. Tumour growth in the groups of conjugate and daunomycin was inhibited by >50% as compared to vehicle treated mice. In contrast to daunomycin treated mice, no weight reduction or death was seen in mice treated with the conjugate. In vivo imaging of the fluorescence signal generated by daunomycin indicated uptake of both conjugate and daunomycin by the tumour. Tumour fluorescence was, however, higher in the conjugate treated mice than in the daunomycin treated mice, thus suggesting specific delivery of the drug to the tumour. Histological examination of myocardial tissue indicated that only the daunomycin, but not conjugate treated mice showed cardiac damage. These results indicate that targeting of daunomycin via carboxymethyldaidzein retains daunomycin's cytotoxic effects while averting its toxicity in an ovarian xenograft.

KW - Daidzein

KW - Daunomycin

KW - Isoflavone

KW - Ovarian carcinoma

KW - Site directed chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=44649093859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44649093859&partnerID=8YFLogxK

U2 - 10.1016/j.jsbmb.2008.03.033

DO - 10.1016/j.jsbmb.2008.03.033

M3 - Article

VL - 110

SP - 144

EP - 149

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1-2

ER -